3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate

3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate is a high‑purity chiral building block supplied by Cosperpharm for the synthesis of endothelin receptor antagonists, a class of therapeutic agents that block the vasoconstrictor peptide ET-1 to treat conditions such as hypertension, heart failure, and diabetic nephropathy. As a key intermediate in the synthesis of atrasentan (ABT‑627) and related compounds, this 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate provides the complete trans,trans‑diaryl pyrrolidine scaffold that serves as the core pharmacophore of these selective ETA antagonists. The mandelic acid salt form enhances the crystallinity and stability of this 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate, enabling reliable handling, accurate weighing, and long‑term storage for both R&D and scale‑up applications. At Cosperpharm, each batch of 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate is supplied with comprehensive analytical documentation and full chiral purity verification to support your drug discovery and API manufacturing programs.

Product Parameters

Product Advantages

1.Defined (2R,3R,4S) absolute configuration – The three contiguous stereocenters are strictly controlled and verified by chiral HPLC, ensuring the correct spatial orientation required for potent ETA receptor antagonism, as established by Abbott Laboratories’ seminal research on A-127722.

2.Established trans,trans-diaryl pyrrolidine pharmacophore – This scaffold was validated through extensive structure‑activity relationship (SAR) studies that identified the optimal 2‑aryl and 4‑aryl substitution patterns for high‑affinity binding and ETA selectivity.

3.Mandelate salt for enhanced stability – The (αS)-α‑hydroxybenzeneacetate (L‑mandelic acid) salt form improves crystallinity, handling properties, and storage stability compared to the free acid, facilitating both R&D and scale‑up workflows.

4.High purity with controlled impurity profile – Each batch is tested to meet ≥98% purity by HPLC, with carefully monitored individual and total impurity levels to support research reproducibility.

5.Fully characterized reference material – Comprehensive analytical data (HPLC, MS, and optional NMR spectra) accompany each shipment, enabling direct use as a reference standard in method development and quality control.

6.Versatile synthetic platform – The carboxylic acid functionality provides a handle for N‑alkylation or amide coupling with various side chains, enabling the synthesis of diverse endothelin antagonist analogs for SAR exploration.

Storage Conditions

Store at 2–8°C (refrigerated) in a tightly sealed, airtight container, protected from light and moisture. The mandelate salt form remains stable for at least 24 months under these recommended conditions. For long‑term storage exceeding 12 months, storage at −20°C is recommended to ensure optimal stability. Avoid repeated freeze‑thaw cycles and exposure to elevated temperatures or high humidity.

Product Applications

1.Endothelin receptor antagonist synthesis – A key building block for the preparation of atrasentan (ABT‑627) and related ETA‑selective antagonists for cardiovascular and renal indications.

2.Structure‑activity relationship (SAR) studies – The carboxylic acid functionality enables introduction of diverse N‑alkyl and N‑acyl substituents, facilitating exploration of the optimal side chain for enhanced potency, selectivity, and oral bioavailability.

3.Analytical method development – Serves as a reference standard for HPLC and LC‑MS method validation for quality control of endothelin receptor antagonist APIs and intermediates.

4.Impurity profiling – Used as a related substance reference standard in process development and impurity tracking during API manufacturing.

5.Process development and scale‑up – Enables monitoring of stereochemical integrity, reaction yields, and impurity formation during the multi‑step synthesis of endothelin receptor antagonists.

6.Regulatory submissions – Provides fully characterized reference material for ANDA, DMF, and IND filings requiring intermediate documentation.

Contact Us

Ready to advance your endothelin receptor antagonist program with 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate? Contact Cosperpharm today for a competitive quotation, product documentation, or a technical consultation with our experienced team.